CorTechs secures new Series B financing

Medical software developer CorTechs Labs, Inc. (CorTechs) is pleased to announce it has secured new Series B financing to support the company's rapid growth. The round was led by Genting Berhad via its indirect wholly-owned subsidiary, Dragasac Limited, a company incorporated in the Isle of Man.

This round of funding will accelerate the development of CorTechs' industry-changing image analysis software and expand its sales and marketing initiatives.

CorTechs is known as the developer of NeuroQuant^®, the leading software solution for the quantification of volumetric brain atrophy to help diagnose a variety of brain disorders.  As the only FDA approved solution that automatically quantifies the volumes of brain structures, NeuroQuant^® is already used by hundreds of neurologists, radiologists and clinical researchers. To date, NeuroQuant^® has been used to scan and analyze over 40,000 brain MRI scans around the world.

"We developed NeuroQuant^® knowing that all aspects of healthcare are becoming more objective and measurement driven. CorTechs is an innovator in the area of software solutions for brain diagnostics in clinical practices. Our objective is to provide superior quantitative measurements to physicians working in all areas of cognitive impairment and neurodegenerative disorders," said Guri Stark, CEO of CorTechs.

"Genting believes there is an untapped market opportunity for CorTechs' products in the field of clinical practices. We are pleased to support CorTechs' initiatives to provide the much needed quantitative brain volumetric information to physicians and radiologists," said Derrik Khoo, a representative of Dragasac Limited.